AKT1

Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)

Retrieved on: 
Monday, November 20, 2023

CAMBRIDGE, United Kingdom, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals (UK), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it is in line to receive a milestone payment from AstraZeneca on first commercial sale of the drug in the US and royalties from AstraZeneca on future sales following the US Food and Drug Administration’s (FDA) approval of Truqap™ plus Faslodex® as a treatment for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN). Eligible patients will have progressed on at least one endocrine-based regimen in the metastatic setting or experienced recurrence on or within 12 months of completing adjuvant therapy.

Key Points: 
  • This is the third cancer drug in the last five years to reach market approval that has been discovered and developed under, or subsequent to, an Astex drug discovery collaboration.
  • Truqap was discovered by AstraZeneca following an earlier drug discovery research collaboration between Astex, The Institute of Cancer Research, London, and Cancer Research Technology (CRT; now Cancer Research Horizons) that was signed in 2003.
  • In 2010, AstraZeneca announced its discovery of Truqap, and began to develop the drug as a potential treatment for various forms of cancer.
  • This is also a great example of UK Biotech-Academia-Pharma collaboration and underlines the strength of the UK life sciences ecosystem.”
    Graphic of the hat-trick of three marketed cancer drugs discovered and developed under, or subsequent to, an Astex drug discovery collaboration with pharma

TRUQAP™ (capivasertib) Now Available from Onco360

Retrieved on: 
Wednesday, November 29, 2023

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by AstraZeneca for Truqap™ (capivasertib).

Key Points: 
  • Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by AstraZeneca for Truqap™ (capivasertib).
  • FDA also approved the FoundationOne®CDx assay as a companion diagnostic device to identify patients with breast cancer for treatment with capivasertib with fulvestrant.
  • “Onco360 is excited to partner with the team at AstraZeneca and become a specialty pharmacy provider for Truqap™,” said Benito Fernandez, Chief Commercial Officer.
  • “We continue to see therapeutic advancements that support our mission; to improve the lives of patients battling cancer, rare, and orphan disease.

City of Hope diabetes experts present new research on beta cells, insulin secretion and islet transplantation at annual American Diabetes Association (ADA) Conference

Retrieved on: 
Tuesday, June 27, 2023

City of Hope diabetes scientists presented research at American Diabetes Association conference.

Key Points: 
  • City of Hope diabetes scientists presented research at American Diabetes Association conference.
  • Sangeeta Dhawan, Ph.D. , an associate professor in City of Hope's Department of Translational Research & Cellular Therapeutics , discussed epigenetic control of beta cell stress response and senescence.
  • Recent research by Dhawan and members of her lab outlined novel findings identifying the mechanisms by which cellular stress causes senescence.
  • Islet transplantation involves isolating insulin producing cells from a donated pancreas and infusing them into a patient with diabetes.

Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine

Retrieved on: 
Thursday, June 8, 2023

The study demonstrated that Capivasertib–fulvestrant combination therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone.

Key Points: 
  • The study demonstrated that Capivasertib–fulvestrant combination therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone.
  • In the study, Burning Rock's flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was used to determine activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN genes for patients enrolled in China.
  • We are proud to have supported our pharma client in such a high impact study, after a rigorous test solution provider evaluation process.
  • [1] Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer.

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Retrieved on: 
Sunday, June 4, 2023

(Jama Network Open, April 2021) and showed that the addition of alisertib to paclitaxel improved progression-free survival (PFS) among enrolled patients compared with paclitaxel alone (HR, 0.56; 95%CI, 0.37-0.84; P = .005).

Key Points: 
  • (Jama Network Open, April 2021) and showed that the addition of alisertib to paclitaxel improved progression-free survival (PFS) among enrolled patients compared with paclitaxel alone (HR, 0.56; 95%CI, 0.37-0.84; P = .005).
  • No mutations were significantly associated with response or resistance to alisertib plus paclitaxel, including those in PIK3CA, TP53, AKT1, HER2, and CDH1.
  • Increased MYC RNA expression was not observed in patients who did not appear to benefit from alisertib plus paclitaxel.
  • This biomarker analysis will be very helpful to the design of the future trials of alisertib that we are planning in hormone receptor positive HER2-negative breast cancer.”

DGAP-News: Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck

Retrieved on: 
Wednesday, September 8, 2021

Merck has completed a multi-institutional Phase I trial led by Apostolia-Maria Tsimberidou, M.D., Ph.D., professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Key Points: 
  • Merck has completed a multi-institutional Phase I trial led by Apostolia-Maria Tsimberidou, M.D., Ph.D., professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
  • Combined with trastuzumab or tamoxifen, DIACC3010 demonstrated early signs of antitumor activity in patients with advanced breast cancer resistant to multiple standard therapies.
  • "We are very proud that, after a highly competitive selection process, Merck has chosen Diaccurate to bring DIACC3010 into advanced clinical development", said Dominique Bridon, Ph.D., CEO of Diaccurate.
  • As part of its plan to develop DIACC3010, Diaccurate has designed an extensive PoC clinical program exploring both incurable solid tumors and refractory hemato-oncology indications.

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

Retrieved on: 
Tuesday, August 17, 2021

PCT/US2020/017053 /) titled, Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization.

Key Points: 
  • PCT/US2020/017053 /) titled, Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization.
  • Judeand UCC have characterized medicinal mushroom Ganoderma lucidum compounds with anti-cancer activity, specifically signicant activity against breast cancer, thus having the potential to treat the most aggressive types of breast cancers such as triple negative breast cancer and inammatory breast cancer.
  • Medicinal mushroom Ganoderma lucidum has been used in traditional Chinese medicine for more than two millennia.
  • Under the terms of the Agreement, Revive gained exclusive worldwide development and commercial rights to intellectual property ( International Patent Application No.

Pipeline Review of RAC Beta Serine/Threonine Protein Kinase - H1, 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 30, 2020

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules.

Key Points: 
  • RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules.
  • The latest report RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H1 2020, outlays comprehensive information on the RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - RAC-beta serine/threonine-protein kinase is an enzyme encoded by the AKT2 gene.
  • Furthermore, this report also reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

RAC Alpha Serine Threonine Protein Kinase - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 17, 2020

The "RAC Alpha Serine Threonine Protein Kinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RAC Alpha Serine Threonine Protein Kinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019'; RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules.
  • RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - RAC-alpha serine/threonine-protein kinase is an enzyme encoded by the AKT1 gene.
  • The report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019' outlays comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

RAC Gamma Serine Threonine Protein Kinase - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 17, 2020

The "RAC Gamma Serine Threonine Protein Kinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RAC Gamma Serine Threonine Protein Kinase - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules.
  • The latest report RAC Gamma SerineThreonine Protein Kinase - Pipeline Review, H2 2019, outlays comprehensive information on the RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • RAC Gamma Serine/Threonine Protein Kinase (Protein Kinase Akt 3 or Protein Kinase B Gamma or RAC PK Gamma or STK 2 or AKT3 or EC 2.7.11.1) - RAC-gamma serine/threonine-protein kinase is an enzyme encoded by the AKT3 gene.